Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera(R)

HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of Biogen's Tecfidera® ca... Biopharmaceuticals, Generics, Neurology, Product Launch Mylan, dimethyl fumarate, Tecfidera, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news